Health Minister Alexandru Rogobete said on Friday that it is "crucial" for Romania to strengthen its capacity to produce safe, modern and affordable medicines.
"It is crucial for Romania to strengthen its capacity to produce safe, modern and affordable medicines, and the project 'Inova A+ Research and Development Center and Production of Critical Medicines', developed by Antibiotice Iasi with the support of the Ministry of Health and the Ministry of European Funds, represents a significant step in this direction. The project, which will directly support the development of the Romanian pharmaceutical industry, will be launched through the STEP (Strategic Technologies for Europe Platform) program. The new center will transform Antibiotice Iasi into a true national hub of pharmaceutical innovation, capable of developing critical medicines and advanced therapeutic solutions, strengthening Romania's independence in the production of essential medicines," Alexandru Rogobete wrote on Facebook.
President Nicusor Dan and Health Minister Alexandru Rogobete visited Antibiotice Iasi on Friday, a strategic company that has made an essential contribution to Romania's pharmaceutical safety.
According to the health minister, Antibiotice Iasi is not just a name with tradition, but "a true pillar of pharmaceutical safety" in Romania and proof that perseverance and professionalism can transform a local company into a benchmark of European performance.
"Its performance is also recognized internationally, with the company being among the top five companies globally in the pharmaceutical sub-industry, according to sustainability indicators (ESG - Environmental, Social, Governance). (...) Antibiotice Iasi shows that when responsibility and sustained work come together, Romania can be an example of excellence in the pharmaceutical field," Rogobete emphasized.
Currently, the company has its own production capacity of over 480 million tablets per year and high-performance flows for the manufacture of capsules, of which 130 million capsules on the penicillin flow and 80 million on the non-penicillin flow.
World leader in the production of Nystatin and one of the most respected companies in Europe in the field of antibiotics, Antibiotice Iasi is a fully integrated company, with over 1,300 employees, a presence in over 50 countries and a stock market capitalization of 1.73 billion lei.
Comentează